RSAR: Post-marketing RX Drug Abuse Surveill Data Denver Health Data Source

Program continuity - Option Year 4 services. Allows FDA to conduct active surveillance of ADEs to inform regulatory actions and abuse prevention programs. Contract to obtain post-marketing prescription and over-the-counter drug abuse surveillance data generated from individuals entering or being assessed for substance abuse treatment. Fund Type Rationale: Funding to ensure program continuity. An increase in funding is proposed to increase the granularity of data for the receipt of additional stratified results. The fund type is split between PDUFA and GDUFA and involves all CDER medical products.

Estimated value

> $25K and < $250K

Est. solicitation date

Jan 1, 2026

Anticipated award

Mar 1, 2026

• NAICS541990
• PSC541990